The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified
This work is licensed under the Creative Commons Attribution 4.0 International License.
Qiu L, Zheng H, Zhao X. The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis. BMC Cancer 2019; 19: 273. doi: 10.1186/s12885-019-5466-yQiuLZhengHZhaoXThe prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis20191927310.1186/s12885-019-5466-yOpen DOISearch in Google Scholar
Minghan Q, Shan W, Xinrui C, Huaqing W. Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting. Cancer Biol Med 2022; 19: 1117–20. doi: 10.20892/j.issn.2095-3941.2022.0403MinghanQShanWXinruiCHuaqingWUpdate on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting20221911172010.20892/j.issn.2095-3941.2022.0403Open DOISearch in Google Scholar
Wang C, Shi F, Liu Y, Zhang Y, Dong L, Li X, et al. Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy. J Hematol Oncol 2021; 14: 106. doi: 10.1186/s13045-021-01120-3WangCShiFLiuYZhangYDongLLiXAnti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy20211410610.1186/s13045-021-01120-3Open DOISearch in Google Scholar
Lu T, Zhang J, Xu-Monette ZY, Young KH. The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma. Exp Hematol Oncol 2023; 12: 72. doi: 10.1186/s40164-023-00432-zLuTZhangJXu-MonetteZYYoungKHThe progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma2023127210.1186/s40164-023-00432-zOpen DOISearch in Google Scholar
Guan J, Zhang J, Zhang X, Yuan Z, Cheng J, Chen B. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials. Medicine 2022; 101: e32333. doi: 10.1097/MD.0000000000032333GuanJZhangJZhangXYuanZChengJChenBEfficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials2022101e3233310.1097/MD.0000000000032333Open DOISearch in Google Scholar
Xie M, Huang X, Ye X, Qian W. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. Int Immunopharmacol 2019; 77: 105999. doi: 10.1016/j.intimp.2019.105999XieMHuangXYeXQianWPrognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma20197710599910.1016/j.intimp.2019.105999Open DOISearch in Google Scholar
Boydell E, Sandoval JL, Michielin O, Obeid M, Addeo A, Friedlaender A. Neoadjuvant immunotherapy: A promising new standard of care. Int J Mol Sci 2023; 24: 11849. doi: 10.3390/ijms241411849BoydellESandovalJLMichielinOObeidMAddeoAFriedlaenderANeoadjuvant immunotherapy: A promising new standard of care2023241184910.3390/ijms241411849Open DOISearch in Google Scholar
Hu LY, Xu XL, Rao HL, Chen J, Lai RC, Huang HQ, et al. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study. Chin J Cancer 2017; 36: 94. doi: 10.1186/s40880-017-0262-zHuLYXuXLRaoHLChenJLaiRCHuangHQExpression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study2017369410.1186/s40880-017-0262-zOpen DOISearch in Google Scholar
Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol 2017; 14: 203–20. doi: 10.1038/nrclinonc.2016.168GoodmanAPatelSPKurzrockRPD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas2017142032010.1038/nrclinonc.2016.168Open DOISearch in Google Scholar
Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology 2017;152: 357–71. doi: 10.1111/imm.12788JelinekTMihalyovaJKascakMDurasJHajekRPD-1/PD-L1 inhibitors in haematological malignancies: update 201720171523577110.1111/imm.12788Open DOISearch in Google Scholar
Ok CY, Young KH. Checkpoint inhibitors in hematological malignancies. J Hematol Oncol 2017; 10: 103. doi: 10.1186/s13045-017-0474-3OkCYYoungKHCheckpoint inhibitors in hematological malignancies20171010310.1186/s13045-017-0474-3Open DOISearch in Google Scholar
Wang Y, Wu L, Tian C, Zhang Y. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas. Ann Hematol 2018; 97: 229–37. doi: 10.1007/s00277-017-3176-6WangYWuLTianCZhangYPD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas2018972293710.1007/s00277-017-3176-6Open DOISearch in Google Scholar
Annibali O, Crescenzi A, Tomarchio V, Pagano A, Bianchi A, Grifoni A, et al. PD-1 /PD-L1 checkpoint in hematological malignancies. Leuk Res 2018; 67: 45–55. doi: 10.1016/j.leukres.2018.01.014AnnibaliOCrescenziATomarchioVPaganoABianchiAGrifoniAPD-1 /PD-L1 checkpoint in hematological malignancies201867455510.1016/j.leukres.2018.01.014Open DOISearch in Google Scholar
Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 2015; 126: 2193–201. doi: 10.1182/blood-2015-02-629600KiyasuJMiyoshiHHirataAArakawaFIchikawaANiinoDExpression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma2015126219320110.1182/blood-2015-02-629600Open DOISearch in Google Scholar
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, WHO classification of tumours, Revised 4th edition, Volume 2. France: International Agency for Research on Cancer; 2017.SwerdlowSHCampoEHarrisNLJaffeESPileriSASteinHRevised 4th edition2FranceInternational Agency for Research on Cancer2017Search in Google Scholar
Fang X, Xiu B, Yang Z, Qiu W, Zhang L, Zhang S, et al. The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. Medicine 2017; 96: e6398. doi: 10.1097/MD.0000000000006398FangXXiuBYangZQiuWZhangLZhangSThe expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma201796e639810.1097/MD.0000000000006398Open DOISearch in Google Scholar
Kwon D, Kim S, Kim PJ, Go H, Nam SJ, Paik JH, et al. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Histopathology 2016; 68: 1079–89. doi: 10.1111/his.12882KwonDKimSKimPJGoHNamSJPaikJHClinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas20166810798910.1111/his.12882Open DOISearch in Google Scholar
Gravelle P, Burroni B, Péricart S, Rossi C, Bezombes C, Tosolini M, et al. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. Oncotarget 2017; 8: 44960–75. doi: 10.18632/oncotarget.16680GravellePBurroniBPéricartSRossiCBezombesCTosoliniMMechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies20178449607510.18632/oncotarget.16680Open DOISearch in Google Scholar
Zeng Q, Liu Z, Liu T. Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis. BMC Cancer 2020; 20: 59. doi: 10.1186/s12885-020-6550-zZengQLiuZLiuTPrognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis2020205910.1186/s12885-020-6550-zOpen DOISearch in Google Scholar
Xie W, Medeiros LJ, Li S, Yin CC, Khoury JD, Xu J. PD-1/PD-L1 pathway and Its blockade in patients with classic Hodgkin lymphoma and Non-Hodgkin large-cell lymphomas. Curr Hematol Malig Rep 2020; 15: 372–81. doi: 10.1007/s11899-020-00589-yXieWMedeirosLJLiSYinCCKhouryJDXuJPD-1/PD-L1 pathway and Its blockade in patients with classic Hodgkin lymphoma and Non-Hodgkin large-cell lymphomas2020153728110.1007/s11899-020-00589-yOpen DOISearch in Google Scholar
Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, Chen BJ. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget 2016; 7: 59976–86. doi: 10.18632/oncotarget.11045XingWDresserKZhangREvensAMYuHWodaBAChenBJPD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications20167599768610.18632/oncotarget.11045Open DOISearch in Google Scholar
Shiozawa E, Yamochi-Onizuka T, Takimoto M, Ota H: The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res 2007; 31: 1579–83. doi: 10.1016/j.leukres.2007.03.017ShiozawaEYamochi-OnizukaTTakimotoMOtaHThe GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries20073115798310.1016/j.leukres.2007.03.017Open DOISearch in Google Scholar
Muenst S, Hoeller S, Willi N, Dirnhofera S, Tzankov A. Diagnostic and prognostic utility of PD-1 in B cell lymphomas. Dis Markers 2010; 29: 47–53. doi: 10.3233/DMA-2010-0725MuenstSHoellerSWilliNDirnhoferaSTzankovADiagnostic and prognostic utility of PD-1 in B cell lymphomas201029475310.3233/DMA-2010-0725Open DOISearch in Google Scholar
Laurent C, Charmpi K, Gravelle P, Tosolini M, Franchet C, Ysebaert L, et al. Several immune escape patterns in non-Hodgkin’s lymphomas. Oncoimmunology 2015; 4: e1026530. doi: 10.1080/2162402X.2015.1026530LaurentCCharmpiKGravellePTosoliniMFranchetCYsebaertLSeveral immune escape patterns in non-Hodgkin’s lymphomas20154e102653010.1080/2162402X.2015.1026530Open DOISearch in Google Scholar
Karakatsanis S, S Papadatos S, Syrigos N, Marinos L, Pouliou E, Papanikolaou A. Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings. J BUON 2021; 26: 569–79.KarakatsanisSS PapadatosSSyrigosNMarinosLPouliouEPapanikolaouAClinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings20212656979Search in Google Scholar
Desouki MM, Post GR, Cherry D, Lazarchick J. PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms. Clin Med Res 2010; 8: 84–8. doi: 10.3121/cmr.2010.891DesoukiMMPostGRCherryDLazarchickJPAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms2010884810.3121/cmr.2010.891Open DOISearch in Google Scholar
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–82. doi: 10.1182/blood-2003-05-1545HansCPWeisenburgerDDGreinerTCGascoyneRDDelabieJOttGConfirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray20041032758210.1182/blood-2003-05-1545Open DOISearch in Google Scholar
Boltezar L, Kloboves-Prevodnik V, Pohar-Perme M, Gasljevic G, Jezersek-Novakovic B. Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma. Oncol Lett 2018; 15: 6903–12. doi: 10.3892/ol.2018.8243BoltezarLKloboves-PrevodnikVPohar-PermeMGasljevicGJezersek-NovakovicBComparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma20181569031210.3892/ol.2018.8243Open DOISearch in Google Scholar
Chen BJ, Dashnamoorthy R, Galera P, Makarenko V, Chang H, Ghosh S, et al. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma. Oncotarget 2019; 10: 2030–40. doi: 10.18632/oncotarget.26771ChenBJDashnamoorthyRGaleraPMakarenkoVChangHGhoshSThe immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma20191020304010.18632/oncotarget.26771Open DOISearch in Google Scholar
Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, et al. Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL. Cancer Immunol Res 2019; 7: 644–57. doi: 10.1158/2326-6066.CIR-18-0439Xu-MonetteZYXiaoMAuQPadmanabhanRXuBHoeNImmune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL201976445710.1158/2326-6066.CIR-18-0439Open DOISearch in Google Scholar
International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329: 987–94. doi: 10.1056/NEJM199309303291402International Non-Hodgkin’s Lymphoma Prognostic Factors ProjectA predictive model for aggressive non-Hodgkin’s lymphoma19933299879410.1056/NEJM199309303291402Open DOISearch in Google Scholar
McCord R, Bolen CR, Koeppen H, Kadel EE 3rd, Oestergaard MZ, Nielsen T, et al. PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv 2019; 3: 531–40. doi: 10.1182/bloodadvances.2018020602McCordRBolenCRKoeppenHKadelEE3rdOestergaardMZNielsenTPD-L1 and tumor-associated macrophages in de novo DLBCL201935314010.1182/bloodadvances.2018020602Open DOISearch in Google Scholar
Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013; 19: 3462–73. doi: 10.1158/1078-0432.CCR-13-0855ChenBJChapuyBOuyangJSunHHRoemerMGXuMLPD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies20131934627310.1158/1078-0432.CCR-13-0855Open DOISearch in Google Scholar
Zhang T, Xie J, Arai S, Wang L, Shi X, Shi N, et al. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget 2016; 7: 73068–79. doi: 10.18632/oncotarget.12230ZhangTXieJAraiSWangLShiXShiNThe efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis20167730687910.18632/oncotarget.12230Open DOISearch in Google Scholar
Kwon HJ, Yang JM, Lee JO, Lee JS, Paik JH. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma. J Transl Med 2018; 16: 320. doi: 10.1186/s12967-018-1689-yKwonHJYangJMLeeJOLeeJSPaikJHClinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma20181632010.1186/s12967-018-1689-yOpen DOISearch in Google Scholar